Exposure-adjusted adverse events comparing blinatumomab with chemotherapy in advanced acute lymphoblastic leukemia

In the phase 3 TOWER study, blinatumomab demonstrated an overall survival benefit over standard-of-care chemotherapy (SOC) in adults with relapsed or refractory (r/r) Philadelphia chromosome–negative (Ph(−)) B-precursor acute lymphoblastic leukemia (ALL). Nearly all patients in both treatment arms e...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Adv
Main Authors: Stein, Anthony S., Larson, Richard A., Schuh, Andre C., Stevenson, William, Lech-Maranda, Ewa, Tran, Qui, Zimmerman, Zachary, Kormany, William, Topp, Max S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2018
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6039663/
https://ncbi.nlm.nih.gov/pubmed/29954814
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018019034
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados